Neulasta Related Published Studies
Well-designed clinical trials related to Neulasta (Pegfilgrastim)
Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: can we decide? [2011.10.31]
Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. [2010.07]
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. [2010.06]
Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. [2010.05]
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. [2010.04]
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. [2010.03.10]
A randomized, placebo-controlled phase ii study evaluating the reduction of
neutropenia and febrile neutropenia in patients with colorectal cancer receiving
pegfilgrastim with every-2-week chemotherapy. [2010]
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. [2009.12.01]
Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support. [2009.12]
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. [2008.11]
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. [2007.09]
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. [2007.07]
Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. [2006.11]
Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. [2006.04]
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. [2005.02.20]
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. [2003.09]
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. [2003.08]
A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. [2003.05]
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. [2003.02.01]
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. [2003.01]
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. [2002.06]
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. [2002.02.01]
Well-designed clinical trials possibly related to Neulasta (Pegfilgrastim)
Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. [2011.01]
A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. [2010]
Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG). [2008.12]
Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. [2008.04.01]
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. [2008.03]
Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. [2007.04.18]
Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. [2006.09]
Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. [2000.07]
Other research related to Neulasta (Pegfilgrastim)
Comparison of pharmacokinetics and safety of pegfilgrastim administered by two
delivery methods: on-body injector and manual injection with a prefilled syringe. [2015]
A randomized, non-inferiority study comparing efficacy and safety of a single
dose of pegfilgrastim versus daily filgrastim in pediatric patients after
autologous peripheral blood stem cell transplant. [2013]
Early versus late administration of pegfilgrastim after high-dose chemotherapy
and autologous hematopoietic stem cell transplantation. [2012]
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33). [2011.11]
Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. [2011.08]
Pharmacokinetics and pharmacodynamics of pegfilgrastim. [2011.05.01]
Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. [2011.03]
Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls. [2011.03]
Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. [2011.01]
Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim. [2011]
[Pegfilgrastim in hematopoietic stem cell transplantation]. [2010.12]
A single dose of Pegfilgrastim versus daily Filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. [2010.12]
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. [2010.10.01]
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study. [2010.09]
Chemotherapy-induced anemia in breast cancer patients treated with pegfilgrastim-supported dose-dense regimens. [2010.06]
Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. [2010.06]
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule. [2010.06]
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies. [2010.05]
[Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany] [2010.03]
Pegfilgrastim in children with severe congenital neutropenia. [2010.03]
Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies. [2010.01]
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. [2010]
Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. [2010]
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat
neutropenia after autologous peripheral blood stem cell transplantation in
patients with non-Hodgkin lymphoma. [2010]
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE
chemotherapy in pediatric sarcoma patients. [2010]
Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous
peripheral blood stem cell support. [2010]
Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. [2009.12]
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen. [2009.12]
Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats. [2009.12]
Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. [2009.11]
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. [2009.10.15]
Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. [2009.09]
Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support. [2009.07.09]
A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. [2009.07]
Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. [2009.07]
Filgrastim and pegfilgrastim use in patients with neutropenia. [2009.06]
Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours. [2009.06]
Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. [2009.05]
Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. [2009.05]
Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT. [2009.05]
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. [2009.04.23]
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. [2009.04]
Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. [2009.03]
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. [2009.03]
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. [2009.03]
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. [2009.02]
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. [2009.01.27]
Pegfilgrastim for peripheral CD34(+) mobilization in patients with solid tumours. [2009.01.26]
Dose-dense induction with sequential-high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de-novo acute myeloid leukemia - a pilot study of the AML-CG. [2009.01.08]
Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. [2009]
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group. [2009]
The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. [2009]
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). [2008.10]
Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. [2008.09]
Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours. [2008.08]
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. [2008.07.10]
Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. [2008.07]
The role of pegfilgrastim in mobilization of hematopoietic stem cells. [2008.06]
Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours. [2008.05.26]
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. [2008.03]
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. [2008.03]
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. [2008.02]
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. [2008.01]
Biological effects of pegfilgrastim on circulating neutrophils in breast cancer patients undergoing dose-dense chemotherapy. [2008]
Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. [2007.12]
Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. [2007.10]
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. [2007.10]
Pegfilgrastim-induced hyperleukocytosis. [2007.09]
In vivo biological effects of pegfilgrastim after myelosuppressive chemotherapy in breast cancer. [2007.09]
Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis. [2007.09]
Florid histiocytic hemophagocytosis following therapy with long acting G-CSF (pegfilgrastim). [2007.08]
|